

Antonio Pérez- Martínez, MD, PhD
Paediatric Haemato-Oncology



Birth date: 05/09/1974:

Personal address: Avenida Monasterio de Silos 24I- 2B. Madrid. 28049. Spain

Work address:

Hospital Universitario La Paz

Paseo de la Castellana 261, Madrid 28046, Spain

Telephone: +34917277223

E-mail: aperezmartinez@salud.madrid.org

SUMMARY

Antonio Pérez-Martínez, graduated from Universidad de Granada with a Bachelor in Medicine (MD) in 1999. Subsequently he completed his training in paediatric haematology–oncology and stem cell transplantation at Hospital Infantil Universitario Niño Jesús, Madrid, Spain (2003). Dr Pérez-Martínez then expanded on his medical experience as a research fellow at the Leukocyte Antigen & Immune Response Foundation, Madrid. Building on this, he completed a PhD investigating haematopoietic mixed chimerism as an adoptive immunotherapy platform in paediatric acute leukaemia at Universidad Autónoma de Madrid. Following postdoctoral research at St. Jude Children Research Hospital, Memphis, Tennessee, US, under the supervision of Wing Leung at Bone Marrow Transplant and Cell therapy department (2006). Dr Pérez-Martínez assumed a staff physician position at the Childhood Haemato-Oncology and Stem Cell Transplantation Department, Hospital Infantil Universitario Niño Jesús, Madrid, Spain (2008). He has reached many national grants to research on tumour cells and Natural Killer (NK) cell crosstalk. The main interest for his research is doing translational research and he is the principal investigator of the first three independent clinical trials in Spain regarding NK cell stimulation and haploidentical transplantation for refractory solid tumours and NK cell expansion for refractory T cell malignancies and myeloma. Since 2009, Dr Pérez-Martínez is Paediatric Associate Professor at the Faculty of Medicine, Universidad Autónoma de Madrid, Spain. Currently, Dr. Pérez-Martínez has published more than 50 articles in international peer-reviewed journals and has presented more than 80 abstracts at scientific meetings. He has been a reviewer for over 5 medical journals and is currently a member of one editorial board.

In 2011, Dr. Pérez-Martínez has received the National Award “Fidel Pagés Miravé” from Spanish Ministry of Defense with the work titled” Kill the killers: Natural Killer cells therapy against paediatric refractory solid tumours”

In addition to his cell therapy research, Dr. Pérez Martínez has developed a national social research strand, has been awarded a Caja Madrid Foundation Prize (2006) in childhood cancer in immigrants and has undertaken an international cooperation program for developing cancer units in low income countries, principally Paraguay, awarded by the International Union Against Cancer (UICC) “My child matters” 2008.

ACADEMIC BACKGROUND AND WORK EXPERIENCE

2013-present	Staff physician. Childhood Haemato-Oncology and Stem Cell Transplantation Department, Hospital Infantil La Paz, Madrid.
2011-present	Plos One Academic Editor.
2011-2011	Postdoctoral research fellowship. Universitätsklinikum Tübingen, Tübingen, Germany. Rupert Handgretinger, MD, PhD (supervisor)
2010-present	Scientist Committee Member CRIS Cancer Foundation
2009-present	Pediatric Associate Professor. Faculty of Medicine. Universidad Autónoma de Madrid, Spain.
2004-2013	Staff physician. Childhood Haemato-Oncology and Stem Cell Transplantation Department, Hospital Infantil Universitario Niño Jesús
2006-2008	Postdoctoral research fellowship. St. Jude Children Research Hospital, Memphis, TN, US. Wing Leung, MD, PhD (supervisor)
2002-2006	Doctor in Medicine, PhD. Universidad Autónoma de Madrid, Spain. Thesis title: "Intentional induction of haematopoietic mixed chimerism as an adoptive immunotherapy platform in paediatric acute leukaemia".
2005	Research Fellow. The Leukocyte Antigen & Immune Response Foundation. Madrid, Spain. Project: Allogeneic transplant in solid tumours.
2003-2005	Diploma in Research Methodology: Design and statistics in health sciences. Universidad Autónoma de Barcelona, Spain.
2002-2004	Clinical fellowship in Paediatric Haematology-Oncology and Stem Cell Transplantation. Hospital Infantil Universitario Niño Jesús, Madrid, Spain.
1999-2002	Clinical fellowship in Pediatrics Hospital Infantil Universitario Niño Jesús, Madrid, Spain.
1992-1999	Bachelor in Medicine, MD. Universidad de Granada, Spain.

PUBLICATIONS:

International Journals

1. Antonio Pérez-Martínez, Lucía Fernández, Jaime Valentín, Isabel Romera, Manuel Ramírez, Sandra Santamaría, Marta González-Vicent, Sara Sirvent, Julián Sevilla, José Luis Vicario, Inmaculada de Prada, Miguel Ángel Díaz. Phase I/II Trial of IL-15-Stimulated Natural Killer Cell Infusion after Haploidentical Stem Cell Transplantation for Pediatric Refractory Solid Tumors. *Cytotherapy* 2015 (accepted).
2. Fernández L, Valentín J, Zalacain M, Leung W, Patiño-García A, Pérez -Martínez A. Activated and expanded natural killer cells target osteosarcoma tumor initiating cells in an NKG2D-NKG2DL dependent manner. *Cancer Lett.* (accepted).
3. Berta González, David Bueno, Pedro Rubio, Sonsoles Sanromán, Diego Plaza, Ana Sastre, Purificación García de Miguel, Lucia Fernández, Jaime Valentín Quiroga, Isabel Martínez, Antonio Pérez Martínez. An immunological approach to acute myeloid leukaemia. *An Pediatr.* 2015 (accepted).
4. Bastos-Oreiro M, Anguita J, Martínez-Laperche C, Fernández L, Buces E, Navarro A, Pascual C, Pérez-Corral A, Balsalobre P, Muñoz C, Kwon M, Serrano D, Perez-Martinez A, Buño I, Gayoso J, Díez-Martín JL. Inhibitory killer cell immunoglobulin-like receptor (iKIR) mismatches improve survival after T-cell-repleted haploidentical transplantation. *Eur J Haematol.* 2015 Jul 1.
5. Pérez-Martínez A, Valentín J, Fernández L, Hernández-Jiménez E, López-Collazo E, Zerbés P, Schwörer E, Nuñez F, Martín IG, Sallis H, Díaz MÁ, Handgretinger R, Pfeiffer MM Arabinoxylan rice bran (MGN-3/Biobran) enhances natural killer cell-mediated cytotoxicity against neuroblastoma in vitro and in vivo. *Cytotherapy.* 2014 Dec 22.
6. Carceller F, Oñoro G, Buitrago MJ, Herrero B, Lassaletta A, Pérez-Martínez A, González-Vicent M, Madero L. Cunninghamella bertholletiae Infection in Children: Review and Report of 2 Cases With Disseminated Infection. *J Pediatr Hematol Oncol.* 2013 Jul 24.
7. Soares-Miranda L, Fiuza-Luces C, Lassaletta A, Santana E, Padilla JR, Fernández-Casanova L, Lorenzo-González R, López-Mojares LM, Pérez M, Pérez-Martínez A, Lucía A. Physical Activity in Pediatric Cancer Patients with Solid Tumors (PAPEC): Trial rationale and design. *Contemp Clin Trials.* 2013 Jun 5.
8. Fernández L, Portugal R, Valentín J, Martín R, Maxwell H, González-Vicent M, Díaz MÁ, de Prada I, Pérez-Martínez A. In vitro Natural Killer Cell Immunotherapy for Medulloblastoma. *Front Oncol.* 2013 Apr 19;3:94.
9. Pérez-Villena A, Cormenzana M, Prada Id, Pérez-Martínez A, Aleo E. Ataxia-telangiectasia and wilms tumor: reduced treatment but early relapse. *J Pediatr Hematol Oncol.* 2013;35:308-10.
10. Chiang SC, Theorell J, Entesarian M, Meeths M, Mastafa M, Al-Herz W, Frisk P, Gilmour KC, Ifversen M, Langenskiöld C, Machaczka M, Naqvi A, Payne J, Perez-Martinez A, Sabel M, Unal E, Unal S, Winiarski J, Nordenskiöld M, Ljunggren HG, Henter JI, Bryceson YT. Comparison of primary human cytotoxic T cell and natural killer cell responses reveal similar molecular requirements for lytic granule exocytosis but differences in cytokine production. *Blood.* 2013.
11. Sevilla J, Guillén M, Castillo A, Prudencio M, González-Vicent M, Lassaletta A, Cormenzana M, Ramírez M, Pérez-Martínez A, Madero L, Díaz-Pérez MÁ. Defining "poor mobilizer" in pediatric patients who need an autologous peripheral blood progenitor cell transplantation. *Cytotherapy.* 2013 Jan;15(1):132-7.

12. Baskin JL, Lezcano E, Kim BS, Figueredo D, Lassaletta A, Perez-Martinez A, Madero L, Caniza MA, Howard SC, Samudio A, Finlay JL. Management of children with brain tumors in Paraguay. *Neuro Oncol.* 2013 Feb;15(2):235-241.
13. Nacif-Gomera ML, Lorenzo-González R, Hernández M, Pérez-Martínez A. AMOR II: An Effort to Eradicate Psychosocial Barriers Induced by Immigration Phenomenon in Children With Cancer. *J Pediatr Hematol Oncol.* 2012 Jul 31.
14. Pérez-Martínez A, de Prada Vicente I, Fernández L, González-Vicent M, Valentín J, Martín R, Maxwell H, Sevilla J, Vicario JL, Angel Díaz M. Natural Killer cells may exert a graft versus tumour effect in haploidentical stem cell transplantation for paediatric solid tumours. *Exp Hematol.* 2012 Jul 4.
15. Herrero B, Ruiz de la Fuente J, Aleo E, Carceller F, Lassaletta A, Orellana MR, Pérez-Martínez A. Spontaneous Resolution of Hypereosinophilic Syndrome in an Infant Without Treatment. *J Pediatr Hematol Oncol.* 2012 Apr 24.
16. Cabeza Martín B, Pérez Suárez E, Iglesias Bouzas MI, Pérez Martínez A, Tamariz Martel A, Aleo E. Syncope in the debut of a mediastinal mass. *Arch Argent Pediatr.* 2012 Apr;110(2):e29-31. Spanish.
17. Pérez-Martínez A, González-Vicent M, Valentín J, Aleo E, Lassaletta A, Sevilla J, Vicario JL, Ramírez M, Díaz MA. Early evaluation of immune reconstitution following allogeneic CD3/CD19-depleted grafts from alternative donors in childhood acute leukemia. *Bone Marrow Transplant.* 2012 Mar 12.
18. Caronia D, Patiño A, Pérez-Martínez A, Pita G, Taisi L, Zalacain-Díez, Molina B, Colmenero I, Sierrasesúmaga L, Benítez J, Gonzalez-Neira A. Effect of ABCB1 and ABCC3 Polymorphisms on Osteosarcoma Survival after Chemotherapy: A Pharmacogenetic Study. *Plos One* 2011 | Volume 6 | Issue 10 | e26091.
19. Oñoro G, Molina B, Lassaletta A, Aleo E, Pérez-Martínez A. Unusual sites of extrapulmonary metastases of osteosarcoma after several lines of treatment. *Pediatric Hematology and Oncology.* 2011.
20. González-Vicent M, Molina B, Andiñ M, Sevilla J, Ramirez M, Pérez A, Díaz MA. Allogeneic hematopoietic transplantation using haploidentical donor vs. unrelated cord blood donor in pediatric patients: a single-center retrospective study. *Eur J Haematol.* 2011;87:46-53.
21. Perez-Martinez A, Iyengar R, Gan K, Chotsampancharoen T, Rooney B, Holladay M, Ramírez M, Leung W. Blood dendritic cells suppress NK cell function and increase the risk of leukemia relapse after hematopoietic cell transplantation. *Biol Blood Marrow Transplant.* 2011;17:598-607.
22. Diaz MA, Lassaletta A, Pérez A, Sevilla J, Madero L, Gonzalez-Vicent M. High-dose busulfan and melphalan as conditioning regimen for autologous peripheral blood progenitor cell transplantation in high-risk ewing sarcoma patients: a long-term follow-up single-center study. *Pediatr Hematol Oncol.* 2010; 27:272-282.
23. Gonzalez-Vicent M, Pérez A, Abad L, Sevilla J, Ramírez M, Díaz MA. Graft manipulation and reduced-intensity conditioning for allogeneic hematopoietic stem cell transplantation from mismatched unrelated and mismatched/haploidentical related donors in pediatric leukemia patients. *J Pediatr Hematol Oncol.* 2010 ;32:e85-90.
24. Chamorro-Viña C, Ruiz JR, Santana-Sosa E, González Vicent M, Madero L, Pérez M, Fleck SJ, Pérez A, Ramírez M, Lucía A. Exercise during hematopoietic stem cell transplant in children. *Med Sci Sports Exerc* 2009.

25. Díaz MA, González-Vicent M, Ramírez M, Sevilla J, Lassaletta A, Pérez A, Madero L. Allogeneic cord blood transplantation in children with hematological malignancies: a long-term follow-up single-center study. *Pediatr Hematol Oncol* 2009; 26:165-174..
26. Lassaletta A, López-Ibor B, Mateos E, González-Vicent M, Pérez-Martínez A, Sevilla J, Díaz MA, Madero L. Intrathecal liposomal cytarabine in children under 4 years with malignant brain tumors. *J Neurooncol* 2009; 95:65-69.
27. Pérez-Martínez A, Leung W, Muñoz E, Iyengar R, Ramírez M, Vicario JL, Lassaletta A, Sevilla J, González-Vicent M, Madero L, Díaz MA. KIR–HLA Receptor-Ligand Mismatch Associated With a Graft-Versus-Tumor Effect in Haploidentical Stem Cell Transplantation for Pediatric Metastatic Solid Tumors. *Pediatr Blood Cancer* 2009; 53:120-124.
28. Sevilla J, González-Vicent M, Lassaletta A, Ramírez M, Pérez-Martínez A, Madero L, Díaz MA. Peripheral blood progenitor cell collection adverse events for childhood allogeneic donors: variables related to the collection and safety profile. *Br J Haematol*. 2008.
29. González-Vicent M, Ramírez M, Pérez A, Lassaletta A, Sevilla J, Díaz MA. Extracorporeal photochemotherapy for steroid-refractory graft-versus-host disease in low-weight pediatric patients. Immunomodulatory effects and clinical outcome. *Haematologica*. 2008 ,93: 1278-1280.
30. Pérez A, González-Vicent M, Ramirez M, Sevilla J, Madero L, Díaz MA. Intentional induction of mixed haematopoietic chimerism as platform for cellular therapy after HLA-matched allogeneic stem cell transplantation in childhood leukaemia patients. *Br J Haematol*. 2008;140: 340-343.
31. García-Castro J, Balas A, Ramírez M, Pérez-Martínez A, Madero L, González-Vicent M, Díaz MA. Mesenchymal stem cells are of recipient origin in pediatric transplantations using umbilical cord blood, peripheral blood, or bone marrow. *J Pediatr Hematol Oncol*. 2007;29: 388-392.
32. Lassaletta A, Pérez-Olleros P, Scaglione C, Sirvent S, De Prada I, Pérez-Martínez A, Ruiz-Hernandez A, Madero L. Successful treatment of intracranial ependymoma with leptomeningeal spread with systemic chemotherapy and intrathecal liposomal cytarabine in a two-year-old child. *J Neurooncol*.
33. Pérez-Martínez A, Del Palacio EC, Nuñez-Polo MH, Olivares JA, Orellana MR, López LM. Childhood cancer in immigration population needs "AMOR" too. *Pediatr Blood Cancer*, Dec 2006.
34. Ramírez M, Lucia A, Gómez-Gallego F, Esteve-Lanao J, Pérez-Martínez A, Foster C, Andreu L, Martín MA, Madero L, Arenas J and García-Castro J. Mobilisation of mesenchymal cells into blood in response to skeletal muscle injury. *Br. J. Sports Med*. 2006; 40:19-722.
35. Pérez-Martínez A, Lassaleta A, Gonzalez-Vicent M, Sevilla J, Díaz MA, Madero L. High-dose chemotherapy with autologous stem cell rescue as first line of treatment in children with high risk and recurrent medulloblastoma and supratentorial primitive neuroectodermal tumours. *J Neuroncol* 2005; 71:33-38.
36. Pérez-Martínez A, Quintero V, Vicent MG, Sevilla J, Díaz MA, Madero L. High-dose chemotherapy with autologous stem cell rescue as first line of treatment in young children with medulloblastoma and supratentorial primitive neuroectodermal tumors. *J Neurooncol*. 2004 Mar-Apr;67(1-2):101-6.

National Journals

37. Martínez I, Fernández L, Valentín J, Castillo C, Chamorro C, Pérez-Martínez A. Natural killer cell cytotoxic activity in critical pediatric patients with suspected hemophagocytic syndrome. *Med Intensiva*. 2014 Jul 28. pii: S0210-5691(14)00141-7.
38. Oñoro G, de Lama G, Pérez-Martínez A, González-Vicent M. Severe hyperphosphoremia and hypocalcemia after the administration of a hypertonic sodium phosphate enema. *Med Intensiva*. 2013 Jul 25.
39. Valentín J, Fernández L, Génesis I, Núñez J, Pérez Martínez A. Kill the Killers: terapia con células Natural Killer en pacientes pediátricos con cancer refractario. *Sanid Mil*. 2012; 68:141-146.
40. Hernández Marqués C, Lassaletta-Atienza A, González-Vicent M, Sevilla J, Molina B, Andión M, Cormenzana M, Pérez Martínez A, Díaz MA, Madero L. Hepatosplenic candidiasis in paediatric haematology-oncology patients. *An Pediatr (Barc)*. 2011.
41. Hernández Núñez-Polo, Lorenzo González R, Catá del Palacio E, López Cabrera A, Martino Alba R, Madero López L, Pérez Martínez A. Talking about death to children with cancer. *An Pediatr (Barc)* 2009; 71: 419-426.
42. Bayona C, Lassaletta A, Pérez A, Sevilla J, ALBI G, Villa JR, Madero L. Hemoptisis fatal secundaria a aspergilosis pulmonar en paciente con leucemia aguda mieloblástica. *An Pediatr (Barc)* 2007; 67:278-279.
43. Catá del Palacio E, Hernández Nuñez-Polo M, Pérez Martínez A, Ramírez M, Madero L. La pérdida en un contexto transnacional: el niño inmigrante con cáncer en fase terminal. *Medicina Paliativa* 2007; 4:236-242.
44. García Castro J, Ramírez M, Pérez Martínez A, Madero L. Terapias celulares en Oncología. *Oncología* 2006; 29:235-237.
45. Pérez-Martínez A, Alonso Ojembarrena A, Ramírez Orellana M, García Castro J, González-Vicent M, Contra Gómez T, Madero López L, Díaz Pérez MA. Twenty years of treating childhood acute lymphoblastic leukaemia. *An Pediatr (Barc)* 2006; 65:198-204.
46. Pérez-Martínez A, Cerezo Bueno MJ, García Penas JJ, Gutiérrez-Solana L, Ruiz-Falco ML. Benign intracranial hypertension and heterozygosity for factor V Leiden mutation. *An Pediatr (Barc)* 2005 Aug; 63:172-4.
47. Barrachina Barbera L, Pérez-Martínez A, Leon Garcia S, Pronzato Cuello F, Martín Arenos J, Tornador E. Cyclic neutropenia with anti-NA2 antibodies and treatment with recombinant granulocyte colony-stimulating factor. *An Pediatr (Barc)* 2005; 63:180-182
48. Pérez Martínez A, Quintero Calcaño V, González Vicent M, Contra Gómez T, Díaz Pérez MA, Madero López L, Sevilla Navarro J. High-dose chemotherapy with autologous stem cell rescue in children with high-risk and recurrent brain tumors]. *An Pediatr (Barc)*. 2004 Jul;61(1):8-15.
49. Martín Díaz MJ, Espejo Moreno L, Hernández Caballero MJ, Díaz Pinazo M, Pérez Martínez A. Measles outbreak in Saharan refugee camps. *An Pediatr (Barc)*. 2004 May;60(5):483-4. IF:0,57.
50. Pérez Martínez A, Contra T, Scaglione C, Díaz Pérez MA, Madero López L. Topotecan for pediatric patients with resistant and recurrent solid tumors]. *An Pediatr (Barc)*. 2003 Aug;59(2):143-8.
51. Pérez Martínez A, Molina Cabañero JC, Quintero Calcaño V, de Vicente Aymat A, de La Torre Espí M. Utility of Boyer's score modified for the differential diagnosis of bacterial and viral meningitis. *An Esp Pediatr*. 2001 Jul;55(1):15-9.

FUNDED RESEARCH PROJECTS**Independent research projects:**

1. Clinical trial (EudraCT: 2015-001901-15): NKCell_LMA_2015 Activated and expanded NK cells infusion as consolidation treatment for paediatric acute myeloid leukemia. Grant: Fundación Mutua Madrileña. Principal Investigator: Antonio Pérez-Martínez.
2. Clinical trial (EudraCT: 2012-000054-63): Activated and expanded NK cells infusion with rescue chemotherapy for paediatric T cell malignancies. Grant: National Health System, Spain. Principal Investigator: Antonio Pérez-Martínez.
3. Clinical Trial (NCT01751243): Transplantation of Hematopoietic Progenitors From Haploidentical Donor With Selective in Vitro Depletion Allo-reactive Lymphocytes in Patient With High Risk Hematological Malignancies. Grant: National Health System, Spain. Collaborator Investigator: Antonio Pérez-Martínez.
4. Clinical Trial: (EC11/036) "Autologous expanded and activated Natural Killer cell infusion for refractory multiple myeloma". Grant: National Health System, Spain. Collaborator Investigator: Antonio Pérez-Martínez.
5. Clinical Trial (EudraCT: 2009-010186-23): Haplotransplant and IL-15 stimulated NK infusion in metastatic solid tumours. Grant: National Health System, Spain. Principal Investigator: Antonio Pérez-Martínez.
6. Traslational research project. NK cell immunotherapy for paediatric solid tumours. Childhood solid tumours and NK cells crosstalk (PS12/01622): Fondo de Investigaciones Sanitarias (FIS), Spain. Principal Investigator: Antonio Pérez-Martínez.
7. Traslational research project. Terapia celular basada en el receptor quimérico NKG2D (CAR-NKG2D) para la leucemia infantil: Fundación uno entrecienmil (2015). Principal Investigator: Antonio Pérez-Martínez.
8. Traslational research project. Childhood solid tumours and NK cells crosstalk (PS09/02393): Fondo de Investigaciones Sanitarias (FIS), Spain. Principal Investigator: Antonio Pérez-Martínez.
9. Traslational research Project, PS09/02393 "Natural Killer cell and tumour cell crosstalk in childhood cancer". Relación Grant: National Health System, Spain. Principal Investigator: Antonio Pérez-Martínez.
10. Research Project (CP07/00056): Innate immune response manipulation for metastatic solid tumours. Grant: National Health System, Spain. Principal Investigator: Antonio Pérez-Martínez.
11. Research Project: Haploidentical stem cell transplantation for malignancies: a platform to explode NK cell alloreactivity. Grant: Mutua Madrileña. Principal Investigator: Antonio Pérez-Martínez.
12. Research Project: "Farmacogenomics in paediatric solid tumours". Proyecto de investigación. "Farmacogenómica en tumores sólidos infantiles". Grant: Asociació Española Contra el Cáncer. Collaborator Investigator: Antonio Pérez-Martínez.
13. Traslational research project. NK cell team. Cancer Research Innovation Spain (CRIS). Principal Investigator: Antonio Pérez-Martínez.

Industry projects:

14. (MK-0869)/(MK0869-208): a multi-center, open-label, 5-part study to evaluate the pharmacokinetics, safety and tolerability of aprepitant and fosaprepitan dimeglumine in pediatric patients receiving emetogenic chemotherapy. Principal Investigator: Antonio Pérez-Martínez.
15. (PGA111081): a multicentre, single arm, observational phase IV study to assess the safety and efficacy of nelarabine in children and young adults (up to 21 years of age) with relapsed or refractory T-lineage acute lymphoblastic leukaemia or lymphoblastic lymphoma. Principal Investigator: Antonio Pérez-Martínez.
16. (MOZ15609) A Phase 1/2 Combined Dose Ranging and Randomised, Open-label, Comparative Study of the Efficacy and Safety of Plerixafor in Addition to Standard Regimens for Mobilisation of Haematopoietic Stem Cells into Peripheral Blood, and Subsequent Collection by Apheresis, Versus Standard Mobilisation Regimens Alone in Paediatric Patients, Aged 2 to <18 Years, with Solid Tumours Eligible for Autologous Transplants. Data Monitoring Committee: Antonio Pérez-Martínez.

More relevant scientist communications:

1. Papel pronóstico de los genes KIR en la evolución postrasplante alogénico familiar HLA idéntico en pacientes pediátricos con leucemia aguda". Comunicación oral. SEOP 2015, Barcelona.
2. Human Activated and Expanded NK Cells Kill Human Osteosarcoma Cells With Characteristics of Cancer Stem Cells in an NKG2D-KNG2D1 Dependent Manner". MD Anderson, Houston, March 2015. (invited by Dr. D. Lee).
3. "Natural Killer cell strategies for cancer treatment". Southampton University, March 2014. (invited by Dr. S. Khakhoo).
4. Avances en la selección de donante haploidéntico para el trasplante de progenitores hematopoyéticos pediátrico. Comunicación oral. SEOP 2014, Tenerife.
5. Memorial "Pablo Ugarte" Workshop. Research on Ewing sarcoma. Immunotherapeutic approach. 2013, Madrid.
6. Haplo-SCT and IL-15 Stimulated NK-Cell-Based Donor Lymphocyte Infusion Post-Transplantation as Treatment for Refractory Solid Tumors. Oral communication at 3rd International Conference on Immunotherapy in Pediatric Oncology, 2012. Frankfurt, Germany.
7. Paediatric sarcomas as target for NK cell immunotherapy. Oral poster at European Science Foundation. ESC 2012. Pulstok, Polonia.
8. Role of the Natural Killer cells in the Recovery of Paediatric Cancer Patients. Key note conference at Benefit of Exercise in the Recovery of Children Undergoing Cancer Treatment Meeting, 2012, Calgary, Canada.
9. Immune reconstitution following CD34 selected grafts and DLI from HLA match related donors in childhood acute leukaemia. Póster at European Bone Marrow Transplantation Meeting 2012. Geneve, Switzerland.
10. Citotoxicidad de las células Natural Killer como herramienta diagnóstica en los syndromes hemofagocíticas. Comunicación oral. SEOP 2012, Pamplona.
11. Haploidentical stem cell transplantation for paediatric refractory solid tumours/ Haploidentical stem cell transplantation and IL-15 NK cell infusion for paediatric refractory solid tumours. Oral communication at Solid Tumour Working Party EMBT group 2011, Brescia, Italy.
12. Immune reconstitution following allogeneic CD3/CD19 depleted graft from alternative donors in childhood acute leukaemia. Oral communication at EBMT 2011, Paris, France.
13. Terapia con células Natural Killer en tumores sólidos refractarios pediátricos. Oral communication at SEOP 2001, Valencia.
14. Childhood Cancer in Africa-improving access to care. Is ALL program feasibility in África?. Oral communication at Continental meeting of International Society of Paediatric Oncology (SIOP) AFRICA 2010, Accra, Ghana.
15. NK cytotoxicity is decreased during the early posttransplant period following pediatric allogeneic transplantation from unrelated donors using CD3/CD19-depleted graft. Póster at Annual meeting of the American Society of Haematology (ASH), 2009, New Orleans, US.
16. Madrid-Asunción twinning in paediatric haemato-oncology, the Asuncion project. Proyecto Asunción: Breeze of Hope, Wind of Change. Oral communication at SIOP meeting 2009, Sao Paulo, Brazil.
17. KIR-HLA receptor ligand mismatch enhances graft versus tumour effect in haploidentical stem cell transplantation in paediatric metastatic solid tumours. Oral communication at satellite EBMT meeting, 2008, Brescia, US.

18. Childhood Cancer in Paraguay. Asunción Project. Oral communication at AHOPCA meeting 2007, Tegucigalpa. Honduras.